Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report)'s share price shot up 5% on Friday. The stock traded as high as $17.26 and last traded at $17.6380. 124,335 shares were traded during trading, a decline of 94% from the average session volume of 2,167,842 shares. The stock had previously closed at $16.80.
Analysts Set New Price Targets
TNDM has been the subject of a number of research reports. Royal Bank Of Canada reissued an "outperform" rating and set a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. UBS Group raised Tandem Diabetes Care from a "neutral" rating to a "buy" rating in a research report on Wednesday. Raymond James Financial upgraded shares of Tandem Diabetes Care from a "market perform" rating to a "strong-buy" rating in a research report on Wednesday. William Blair initiated coverage on shares of Tandem Diabetes Care in a research note on Friday, August 21st. They set an "outperform" rating on the stock. Finally, Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a research note on Friday, November 6th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $27.39.
Read Our Latest Stock Report on Tandem Diabetes Care
Tandem Diabetes Care Stock Up 4.2%
The company has a market capitalization of $1.22 billion, a PE ratio of -24.28 and a beta of 1.59. The company has a debt-to-equity ratio of 4.47, a quick ratio of 2.65 and a current ratio of 3.20. The company's 50-day moving average is $17.24 and its 200 day moving average is $18.79.
Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.15. The company had revenue of $283.69 million for the quarter, compared to analysts' expectations of $265.85 million. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. Tandem Diabetes Care's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.31) EPS. As a group, analysts anticipate that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current year.
Insider Buying and Selling at Tandem Diabetes Care
In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company's stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the completion of the sale, the director owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Tandem Diabetes Care during the 2nd quarter worth approximately $33,000. Sterling Capital Management LLC increased its holdings in Tandem Diabetes Care by 849.0% in the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company's stock valued at $38,000 after buying an additional 2,080 shares in the last quarter. Fulcrum Asset Management LLP raised its position in shares of Tandem Diabetes Care by 1,463.6% in the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company's stock worth $73,000 after acquiring an additional 4,098 shares during the period. Prosperitas Financial LLC acquired a new position in shares of Tandem Diabetes Care in the second quarter worth about $151,000. Finally, Provenance Wealth Advisors LLC purchased a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth about $158,000.
About Tandem Diabetes Care
(
Get Free Report)
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company's offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tandem Diabetes Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.
While Tandem Diabetes Care currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.